A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

Summary

The purpose of this study is to assess the effect and safety of AZD6765 in patients with major depressive disorder who exhibit inadequate response to antidepressants. AZD6765 is a channel blocker of the N-methyl-D-aspartate (NMDA) class of glutamate receptors.

Timeline

Start

2011-12-16

Primary completion

2013-08-26

Completion

2013-08-26

Drugs

Indications